Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs
, , , , , y
20 ago 2020
Acerca de este artículo
Publicado en línea: 20 ago 2020
Páginas: 45 - 55
Recibido: 29 abr 2020
Aceptado: 28 may 2020
DOI: https://doi.org/10.2478/acm-2020-0006
Palabras clave
© 2020 K Prso et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible